INDIA LIVE DESKNIFTY 50:23,140.50(+0.34%)SENSEX:73,895.74(+0.43%)
RDU Global
🇮🇳
Home/Topics/Companies & Institutions/Abogen Biosciences
Back to Newsroom
🏢Organization Dossier

Abogen Biosciences

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

6 Stories Indexed
Last Updated: Just Now
Verified Entity Intelligence
Global Health & Biotech 04 Oct 2026, 08:22 AM IST

Novartis Agrees to Up to $7.8 Billion mRNA Deal With China’s Abogen

Novartis has struck a licensing and development agreement with Chinese biotech Abogen Biosciences that could be worth as much as $7.8 billion, underscoring the Swiss drugmaker’s push into next-generation cancer therapies. The deal centers on an mRNA-encoded T-cell engager, a highly targeted approach that has drawn intense interest from large pharmaceutical companies seeking to replenish pipelines and deepen exposure to innovative Chinese science.

By RDU Global Wire6 min read
Frontier AI & Machine Learning15 Oct 2026, 11:54 PM IST

Colossal Biosciences Unveils AI Platform to Speed De-Extinction Push as Diamandis Launches Backing Fund

Colossal Biosciences has introduced a new artificial intelligence platform designed to accelerate its de-extinction research, adding a software layer to one of the most ambitious biotechnology programs in the frontier science sector. The announcement comes as entrepreneur Peter Diamandis launches a new fund aimed at backing startups that build on the platform, signaling fresh investor interest in AI-enabled synthetic biology.

5 min readRead →
Frontier AI & Machine Learning15 Oct 2026, 05:44 PM IST

Colossal Biosciences Unveils AI Platform to Speed De-Extinction Work, Drawing New Backing From Peter Diamandis

Colossal Biosciences has introduced a new artificial intelligence platform designed to accelerate its de-extinction research, adding a software layer to a field long dominated by genomics, reproductive science and conservation biology. The move underscores how frontier AI is increasingly being positioned as a force multiplier in high-risk life sciences, while Peter Diamandis has launched a new fund aimed at backing startups that build on the platform.

6 min readRead →
Global Economy & Central Banks12 Oct 2026, 10:55 AM IST

Colossal’s De-Extinction Push Raises a Bigger Question: Can Ancient DNA Help Extend Human Life?

Colossal Biosciences chief executive Ben Lamm is arguing that efforts to bring back extinct species such as dire wolves and woolly mammoths are not merely a spectacle of biotechnology, but a platform for conservation, healthcare and developmental biology. The company’s pitch places de-extinction within a broader scientific and commercial race to master genome engineering, with possible spillovers into human medicine and longevity research.

5 min readRead →
Global Economy & Central Banks12 Oct 2026, 10:14 AM IST

De-Extinction Push Gains Economic Weight as Colossal Links Dire Wolves, Mammoths to Human Longevity

Colossal Biosciences CEO Ben Lamm is arguing that efforts to bring back extinct species such as dire wolves and woolly mammoths could have value far beyond spectacle, with potential spillovers into conservation, healthcare and developmental biology. The pitch places de-extinction within a broader innovation economy, where advances in gene editing, reproductive science and ecosystem restoration may eventually inform human medicine and longevity research.

6 min readRead →
Clean Energy & Climate Transition12 Oct 2026, 12:38 AM IST

De-Extinction Push Raises Bigger Questions for Climate Tech, Biodiversity and Human Health

A new wave of de-extinction research, led by Colossal Biosciences and amplified by media coverage of dire wolves and woolly mammoths, is being framed not just as a scientific spectacle but as a potential platform for conservation and climate innovation. Advocates argue the same genetic tools could strengthen endangered species and ecosystem resilience, while critics warn the field risks overselling speculative benefits and diverting attention from existing biodiversity crises.

5 min readRead →

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Abogen Biosciences: